Unverified50% confidenceBenchmarkExact time
The results of the PURPOSE 1 clinical trial published in 2024 showed that subcutaneous injection of lenacapavir once every six months achieved 100% HIV prevention efficacy (zero infections) in young women.
1
Sources
50%
Confidence
Medium-term (~90 days)
Relevance
9/4/2026
First Seen
Valid until: 12/3/2026
Sources
Related Entities
Cite This Claim
Stable URI
https://kongchang.com/claim/852346API
curl https://kongchang.com/api/v1/knowledge/claims/852346MCP
get_claim(id=852346)